Research & Development
Mifcare designs and develops first-in-class, orally-available small molecule inhibitors of macrophage migration inhibitory factor (MIF), a pro-inflammatory cytokine strongly involved in the pathogenesis of pulmonary arterial hypertension (PAH).
MFC1040, currently in preclinical development is the most advanced compound. Thanks to its unique mechanism of action, MFC1040 is able to markedly reduce inflammation in and around the pulmonary vessels in animal models of PAH. Inflammation is considered as a primary component of PAH pathogenesis.